Ann: Becoming a substantial holder, page-13

The company has zero debt. Insanely high margins. Has some $100M cash at the bank. Only got to 2% of their potential market. And it's market price is some $680M, or $580M after the cash if you're buying it outright.

Now with new research showing their product can be an alternative to an existing treatment, or be use in combination with chemotherapy to greatly reduce tumour, improve quality of life for salvage patients. It's just a no brainer buying at these prices.